{"id":"etoposide-usual","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Myelosuppression"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-15%","effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL1200645","moleculeType":"Small molecule","molecularWeight":"668.54"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting topoisomerase II, etoposide causes DNA damage and triggers apoptosis in rapidly dividing cancer cells. This leads to cell death and ultimately, tumor shrinkage. Etoposide is most effective against cancers with high rates of cell division, such as leukemia and lymphoma.","oneSentence":"Etoposide is a topoisomerase II inhibitor that works by interfering with the enzyme topoisomerase II, which is involved in DNA replication and cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:52:13.484Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia"},{"name":"Small cell lung cancer"},{"name":"Testicular cancer"},{"name":"Hodgkin's lymphoma"},{"name":"Non-Hodgkin's lymphoma"}]},"trialDetails":[{"nctId":"NCT04301076","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":"Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma","enrollment":30},{"nctId":"NCT03983824","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-05-05","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":48},{"nctId":"NCT03984448","phase":"PHASE2, PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-22","conditions":"Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma","enrollment":363},{"nctId":"NCT03811002","phase":"PHASE3","title":"Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-26","conditions":"Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8","enrollment":544},{"nctId":"NCT04803201","phase":"PHASE2","title":"Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma","status":"SUSPENDED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2021-10-08","conditions":"Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma","enrollment":170},{"nctId":"NCT07357623","phase":"PHASE2","title":"Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-09-22","conditions":"Pulmonary Neuroendocrine Tumor","enrollment":96},{"nctId":"NCT05624996","phase":"PHASE3","title":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-07-12","conditions":"Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8","enrollment":474},{"nctId":"NCT04631029","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-27","conditions":"Extensive Stage Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain","enrollment":3},{"nctId":"NCT01064466","phase":"PHASE2, PHASE3","title":"Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","startDate":"2025-07-16","conditions":"Small Cell Lung Cancer","enrollment":600},{"nctId":"NCT04712903","phase":"PHASE3","title":"Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-12-16","conditions":"Small Cell Lung Carcinoma Extensive Disease","enrollment":101},{"nctId":"NCT05444712","phase":"NA","title":"Transplantation After Complete Response In Patients With T-cell Lymphoma","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2022-08-01","conditions":"Peripheral T Cell Lymphoma","enrollment":204},{"nctId":"NCT04989283","phase":"PHASE2","title":"Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2021-09-09","conditions":"Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":""},{"nctId":"NCT00118209","phase":"PHASE3","title":"Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2005-05","conditions":"Large B Cell Lymphoma","enrollment":524},{"nctId":"NCT00281879","phase":"PHASE2","title":"Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-02","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":200},{"nctId":"NCT03188198","phase":"PHASE2","title":"Risk Adapted Therapy in Diffuse Large B Cell Lymphoma","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2016-06-01","conditions":"Large B Cell Lymphoma","enrollment":60},{"nctId":"NCT00577096","phase":"NA","title":"Effects of Exercise in Combination With Epoetin Alfa","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2001-10","conditions":"Multiple Myeloma","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Usual Etoposide Capsule Chemotherapy"],"phase":"phase_2","status":"active","brandName":"ETOPOSIDE - Usual","genericName":"ETOPOSIDE - Usual","companyName":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","companyId":"han-xu-m-d-ph-d-fapcr-sponsor-investigator-irb-chair","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etoposide is a topoisomerase II inhibitor that works by interfering with the enzyme topoisomerase II, which is involved in DNA replication and cell division. Used for Acute lymphoblastic leukemia, Small cell lung cancer, Testicular cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}